These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38830000)

  • 1. Impact of the COVID-19 Pandemic on Functions of Nursing Professionals in the Care of Opioid Use Disorder: Systematic Review.
    Brown KG; Chen CY; Dong D; Lake KJ; Butelman ER
    J Addict Nurs; 2024 Apr-Jun 01; 35(2):107-113. PubMed ID: 38830000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.
    Alexander K; Pogorzelska-Maziarz M; Gerolamo A; Hassen N; Kelly EL; Rising KL
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):60. PubMed ID: 34372900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "How will I get my next week's script?" Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic.
    Krawczyk N; Bunting AM; Frank D; Arshonsky J; Gu Y; Friedman SR; Bragg MA
    Int J Drug Policy; 2021 Jun; 92():103140. PubMed ID: 33558165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
    Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
    Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
    Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
    J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
    Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
    [No Abstract]   [Full Text] [Related]  

  • 11. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
    Saloner B; Krawczyk N; Solomon K; Allen ST; Morris M; Haney K; Sherman SG
    Int J Drug Policy; 2022 Mar; 101():103537. PubMed ID: 34871945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
    Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
    Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
    Cremer LJ; Board A; Guy GP; Schieber L; Asher A; Parker EM
    Drug Alcohol Depend; 2022 Mar; 232():109192. PubMed ID: 35065513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.